Last reviewed 2026-04-20 · How we verify

Ticarcillin (TICARCILLIN DISODIUM)

Ticarcillin disodium is a penicillin-class antibacterial medication originally developed by Beecham Group and currently owned by Sandoz. It is a small molecule modality with a half-life of 1.0 hours and 0% bioavailability. Ticarcillin disodium is approved to treat various bacterial infections, including lung abscess, aspiration pneumonia, and urinary tract infections. The medication is off-patent and available as a generic product. Key safety considerations include its potential to cause allergic reactions and interactions with other medications.

At a glance

Approved indications

• Abscess of lung
• Aspiration pneumonia
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial infection due to Serratia
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Bacteroides Endometritis
• Bacteroides Peritonitis
• Citrobacter Urinary Tract Infection
• Complicated Genitourinary Tract Infection
• Complicated Urinary Tract Infections
• E. Coli Endometritis
• E. Coli Peritonitis
• Empyema of pleura
• Enterobacter Endometritis
• Enterobacter Pneumonia
• Escherichia coli urinary tract infection
• Genitourinary Tract Infections
• Haemophilus influenzae pneumonia

Common side effects

No common side effects on file.

Drug interactions

• tobramycin

Key clinical trials

• Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio) (PHASE1)
• The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (NA)
• Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD (PHASE2,PHASE3)
• Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
• A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (PHASE4)
• An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) (PHASE2)
• Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients (PHASE2)
• WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.